BMS 986231

Drug Profile

BMS 986231

Alternative Names: BMS-986231; BMS-986231-01; CXL 1427; HNO Donor; HNO Nitroxyl Donor

Latest Information Update: 01 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardioxyl Pharmaceuticals
  • Developer Bristol-Myers Squibb
  • Class Heart failure therapies
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute heart failure; Heart failure

Most Recent Events

  • 30 Nov 2017 Phase-II clinical trials in Heart failure in United Kingdom (IV) (NCT03357731)
  • 14 Nov 2017 Bristol-Myers Squibb plans a phase II/III trial for Cardiovascular disease
  • 09 Nov 2017 Bristol-Myers Squibb plans a phase I trial in patients with different levels of kidney function in Czech Republic and Poland in December 2017 (NCT03332186)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top